Defeating cancer together: our policy priorities
We believe there are three areas the Government could prioritise to enable cancer research in academic institutions to thrive, and help us on our mission to continue making the discoveries that defeat cancer.
"We need the Government to use all available policy levers to support the sector and help cancer research in UK academic institutions thrive."
- Professor Kristian Helin, Chief Executive, The Institute of Cancer Research
"100 days in - it is vital that this new Parliament comes together to prioritise cancer research. For all of us affected by cancer, research is where hope starts, Parliament can help catalyse this hope"
- Sue Duncombe, Cancer Patient Advocate
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
The ICR honoured for vital role in advancing research-driven care for children with brain tumours
The Royal Marsden Hospital, St George's Hospital and King's College Hospital with The Institute of Cancer Research, London, as the South London Paediatric Neuro-Oncology Network, has announced that it has been designated a Tessa Jowell Centre of Excellence for Children.
New AI models set to revolutionise medical imaging and transform cancer care
Two ground-breaking studies have demonstrated that combining artificial intelligence (AI) with state-of-the-art MRI imaging could revolutionise how clinicians detect, monitor and treat advanced prostate cancer.
ICR responds to announcement of prostate cancer screening for men with BRCA1 and BRCA2 gene mutations
Experts at The Institute of Cancer Research, London, have responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme for men with a confirmed BRCA1 and BRCA2 variant.